ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA), 2005 y\u0131l\u0131nda tip II diyabet tedavisi i\u00e7in Byetta'y\u0131 (aktif madde exenatide) onaylad\u0131. Enjeksiyon yoluyla verilen milyonlarca ki\u015fi, kan \u015fekerini d\u00fc\u015f\u00fcrmek i\u00e7in Byetta ald\u0131. Federal onay\u0131na ra\u011fmen, Byetta hem kusurlu hem de tehlikeli bir ila\u00e7 oldu\u011funu kan\u0131tlad\u0131. Byetta'y\u0131 ald\u0131ysan\u0131z ve sonu\u00e7 olarak zarar g\u00f6rd\u00fcyseniz, bir avukat tazminat talebinde bulunman\u0131za yard\u0131mc\u0131 olabilir.<\/p>\n
<\/p>\n
Napoli Shkolnik, PLLC is currently investigating cases for patients who have been diagnosed pancreatic cancer and thyroid cancer\u00a0while taking or after taking Byetta. These are potentially life-threatening conditions that may have a tremendous impact on a patient and his or her family, and we are prepared to seek financial compensation that can cover medical bills, lost income and the other losses and injuries associate with these side effects. Contact our offices today, or continue reading to learn more about this type 2 diabetes medication and the side effects it may cause.<\/p>\n
One of the most recent developments in Byetta side effects involves pancreatic cancer. According to a new study by researchers at the University of California, Los Angeles (UCLA), evidence of pre-cancerous cellular changes were found in diabetic patients taking incretin mimetics. The Food and Drug Administration (FDA) released a Drug Safety Communication regarding this new study in March of 2013, stating that the agency would evaluate the findings of this study. Incretin mimetics are a class of diabetic drugs, including Byetta, Januvia, Victoza and several others.<\/p>\n
<\/p>\n
Since it was approved by the U.S. Food and Drug Administration in 2005, millions of prescriptions for Byetta (exenatide) have been dispensed across the nation. From 2005 through 2009 alone, 7 million Byetta prescriptions were dispensed. Byetta is an injectable prescription medication for the treatment of type 2 diabetes, injected twice daily within 60 minutes before the first and last meals of the day. It stimulates the production of insulin in the pancreas and causes the stomach to empty itself more slowly. Combined with diet and exercise and possibly other diabetes medications, Byetta is meant to bring blood sugar to a more optimum level.<\/p>\n
Byetta is not a cure for type 2 diabetes, a condition that has been diagnosed in millions of Americans. It is instead meant to control this type of diabetes by stimulating insulin production. It is estimated that many more Americans are at risk of developing type 2 diabetes or are unaware that they are in the early stages of the condition.<\/p>\n
With the number of patients currently suffering from type 2 diabetes, it is no wonder that so many Byetta prescriptions have been written and filled. Unfortunately, as the drug increased in popularity it became evident that patients were suffering from serious side effects.<\/p>\n
<\/p>\n
Byetta, baz\u0131lar\u0131 tedavi edilmedi\u011fi takdirde \u00f6l\u00fcmc\u00fcl olabilen bir dizi ciddi sa\u011fl\u0131k sorunuyla ili\u015fkilendirilmi\u015ftir. Bunlar \u015funlar\u0131 i\u00e7erir:<\/p>\n
Asl\u0131nda, 2005 ve 2008 y\u0131llar\u0131 aras\u0131nda FDA, B\u00f6brek sorunlar\u0131 geli\u015fen hastalar\u0131n 78 raporu<\/a> Byetta'y\u0131 alman\u0131n do\u011frudan bir sonucu olarak. Bunlardan 18'i diyalize, ikisi b\u00f6brek nakline ihtiya\u00e7 duydu ve d\u00f6rd\u00fc \u00f6ld\u00fc.<\/p>\n <\/p>\n Byetta'y\u0131 alman\u0131n do\u011frudan bir sonucu olarak zarar g\u00f6rd\u00fc\u011f\u00fcn\u00fcze inan\u0131yorsan\u0131z, Byetta'n\u0131n \u00fcreticisi olan Amylin Pharmaceuticals'a veya \u00fcretim veya da\u011f\u0131t\u0131m zincirindeki ba\u015fka bir tarafa kar\u015f\u0131 dava a\u00e7abilirsiniz. Bir hukuk davas\u0131nda zarar\u0131n tazmin edilebilmesi i\u00e7in, ila\u00e7 \u00fcreticisinin ihmalinin ve ay\u0131pl\u0131 ilac\u0131n size zarar verdi\u011fini kan\u0131tlaman\u0131z gerekecektir. \u0130hmal \u00f6rnekleri \u015funlar\u0131 i\u00e7erebilir:<\/p>\n Ayr\u0131ca Byetta'y\u0131 almad\u0131\u011f\u0131n\u0131z takdirde zarar\u0131n\u0131z\u0131n do\u011fmayaca\u011f\u0131n\u0131 da kan\u0131tlaman\u0131z gerekecektir.<\/p>\n <\/p>\n Although Byetta is still approved for the treatment of type 2 diabetes in adults, it is possible that patients may experience serious and life-changing side effects. Some may even be at risk of losing their lives from these. Those who have suffered injury of this kind may be entitled to financial compensation for pain, suffering, medical care and lost earnings. Future medical expenses and loss of future earnings may also be covered, depending on the case.<\/p>\n Since 2000 alone, the attorneys at Napoli Shkolnik, PLLC have recovered in excess of $2 billion in settlements and awards. We are fully committed to representing the interests of the injured, helping them seek justice in the wake of the physical pain, emotional trauma and financial losses they have experienced. We go up against the most formidable opponents, negotiating fair settlements and fighting for favorable verdicts in order to help our clients begin rebuilding and moving on with their lives. We are ready to see how we can help with your Byetta lawsuit and welcome you to temas etmek<\/a> a ila\u00e7 dava avukat\u0131<\/a> at our law office to discuss your rights and options. Your initial consultation is free.<\/p>\n Depending upon the state in which you live, the statute of limitations for filing a defective drug claim is usually between two and four years from the date of discovery of illness. To ensure that you file a claim within the time limits, make sure you contact the attorneys at Napoli Shkolnik, PLLC as soon as possible. We are ready to meet with you today!<\/p>","protected":false},"excerpt":{"rendered":" ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA), 2005 y\u0131l\u0131nda tip II diyabet tedavisi i\u00e7in Byetta'y\u0131 (aktif madde exenatide) onaylad\u0131. Enjeksiyon yoluyla verilen milyonlarca ki\u015fi Byetta ald\u0131\u2026<\/p>","protected":false},"featured_media":0,"menu_order":59,"template":"","practiceareas_category":[743],"class_list":["post-5670","practiceareas","type-practiceareas","status-publish","hentry","practiceareas_category-pharmaceutical-litigation"],"acf":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas\/5670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/types\/practiceareas"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas\/5670\/revisions"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/media?parent=5670"}],"wp:term":[{"taxonomy":"practiceareas_category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas_category?post=5670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Byetta'n\u0131n \u00dcreticisine Kar\u015f\u0131 Bir Dava Nedenim Var m\u0131?<\/h3>\n
\n
Zararlar\u0131 Tazmin Etmek \u0130\u00e7in Hemen Yasal \u0130\u015fleme Ba\u015flay\u0131n<\/h3>\n